InflaRx NV IFRX.OQ, IFRX.O is expected to show a rise in quarterly revenue when it reports results on March 19 for the period ending December 31 2025
The Jena Thueringen-based company is expected to report a 11,671.0% decrease in revenue to €115.71 thousand from €-1 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for InflaRx NV is for a loss of 15 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for InflaRx NV is $7.00, about 669.2% above its last closing price of $0.91
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.15 | -0.15 | -0.18 | Missed | -18.9 |
Jun. 30 2025 | -0.19 | -0.18 | -0.21 | Missed | -13.5 |
Mar. 31 2025 | -0.19 | -0.18 | -0.13 | Beat | 29.3 |
Dec. 31 2024 | -0.25 | -0.08 | Beat | 68 | |
Sep. 30 2024 | -0.25 | -0.25 | -0.30 | Missed | -20 |
Jun. 30 2024 | -0.20 | -0.20 | -0.24 | Missed | -21.5 |
Mar. 31 2024 | -0.22 | -0.22 | -0.17 | Beat | 23.6 |
Dec. 31 2023 | -0.14 | -0.18 | -0.27 | Missed | -47.9 |
This summary was machine generated March 17 at 12:59 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments